Country: Canada
Language: English
Source: Health Canada
FINGOLIMOD (FINGOLIMOD HYDROCHLORIDE)
TARO PHARMACEUTICALS INC
L04AE01
FINGOLIMOD
0.5MG
CAPSULE
FINGOLIMOD (FINGOLIMOD HYDROCHLORIDE) 0.5MG
ORAL
28/30
Prescription
Immunomodulatory Agents
Active ingredient group (AIG) number: 0152886001; AHFS:
APPROVED
2019-03-11
_Taro-Fingolimod (Fingolimod Capsules) _ _ _ _Page 1 of 66 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr TARO-FINGOLIMOD Fingolimod Capsules Capsules, 0.5 mg fingolimod (as fingolimod hydrochloride), Oral Taro Standard Sphingosine 1-phosphate receptor modulator Taro Pharmaceuticals Inc. Date of Initial Authorization: 130 East Drive, Brampton March 11, 2019 Ontario L6T 1C1 Date of Revision: February 21, 2022 Submission Control No: 256647 _Taro-Fingolimod (Fingolimod Capsules) _ _ _ _Page 2 of 66 _ RECENT MAJOR LABEL CHANGE 2 CONTRAINDICATIONS February, 2022 4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations; 4.2 Recommended Dose and Dosage Adjustment; 4.4 Administration; 4.5 Missed Dose February, 2022 7 WARNINGS AND PRECAUTIONS, 7.1 Special Populations February, 2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGE..................................................................................................... 2 TABLE OF CONTENTS ..................................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION............................................................................. 4 1 INDICATIONS ......................................................................................................................... 4 1.1 Pediatrics ........................................................................................................................... 4 1.2 Geriatrics ........................................................................................................................... 4 2 CONTRAINDICATIONS ............................................................................................................ 4 4 DOSAGE AND ADMINISTRATION............................................................................................ 5 4.1 Dosing Considerations ..................................................... Read the complete document